21 May 2026
The right therapy for right heart failure and tricuspid regurgitation: fixing my patient congestion, not just a valve
Sponsored by Products & Features
Summary
This EuroPCR 2026 session shifts the focus in tricuspid regurgitation from anatomy alone to the broader context of right heart failure and systemic congestion. It highlights the limitations of purely leaflet-based strategies, particularly in advanced disease and in the presence of severe right ventricular dysfunction.
The discussion addresses the impact of residual tricuspid regurgitation after edge-to-edge repair and explores alternative approaches, including heterotopic bicaval valve implantation with the TricValve system. Case-based experience helps refine patient selection and identify when conventional repair or replacement strategies may be insufficient, emphasising a more individualised approach centred on symptoms, haemodynamics, and congestion relief.
Learning Objectives
- To recognise the simplistic nature and limitations of a solely anatomy-based tricuspid treatment algorithm, and the importance of incorporating clinical factors
- To discuss why residual severe tricuspid regurgitation after edge-to-edge repair represents a suboptimal clinical outcome
- To understand why severe right ventricular dysfunction identifies patients at high risk for orthotopic tricuspid replacement
- To identify patient cohort in which heterotopic bicaval valve implantation may provide superior safety, symptomatic and hemodynamic benefit compared to TEER or orthotopic replacement
- To identify when and why leaflet-directed therapies may be insufficient in advanced stages of right heart failure
